On Thursday, Shares of Procter & Gamble Co (NYSE:PG), added 0.42% and closed at $89.22 in the last trading session. The last trading range of the stock ranges between $88.47 and $89.73. The People’s Choice Awards and CBS declared recently that PEOPLE’S CHOICE AWARDS 2017 will air live on Wednesday, January 18, 2017 (9:00-11:00 PM, ET/delayed PT) from Microsoft Theater in Los Angeles on the CBS Television Network.
Mark Burnett, President of MGM Television and Digital, will return for the eighth successive year as Executive Producer of the show. Also returning, Jane Mun, Kimmie H. Kim and Fred Nelson will serve alongside Burnett as Executive Producers of the telecast.
“It is an honor to be back again and work with a team that is one of the finest in the business,” said Burnett. “This show is so unique as the fans get to choose all the winners and it is up to them who comes to the stage. We are looking forward to another great event.”
Exelixis, Inc. (NASDAQ:EXEL), jumped 0.46% and closed at $13.18 in the last trading session. The last trading range of the stock ranges between $12.74 and $13.35. The company’s Market capitalization is $3.20 Billion with the total Outstanding Shares of 230.33 Million. Exelixis, Inc. (EXEL) recently declared that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with formerly untreated BRAF V600 mutation-positive advanced melanoma. The results will be the subject of a poster negotiation presentation (Abstract #1109PD) at the European Society of Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11 in Copenhagen, Denmark. Patrick Hwu, M.D., chair of the Department of Melanoma Medical Oncology at the University of Texas M.D. Anderson Cancer Center, Houston, Texas, will present the results during a session on Monday, October 10, 2016, starting at 11:00 a.m. CEST.
“Cobimetinib and vemurafenib is FDA-approved to treat specific forms of BRAF V600 mutation-positive unresectable or metastatic melanoma and has been associated with noteworthyimprovements in progression-free survival, overall survival and objective response rate as contrast to vemurafenib alone,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “The preliminary results to be presented at the ESMO Congress suggest that adding atezolizumab to the combination regimen is associated both with a manageable safety profile and promising antitumor activity.”
Range Resources Corp. (NYSE:RRC), lost -1.44% and closed at $38.45 in the last trading session. The last trading range of the stock ranges between $38.06 and $39.35. During the 52-week trading session the minimum price at which share price traded, registered at $19.21 and reached to max level of $46.96. RANGE RESOURCES CORPORATION (RRC) declared recently that its third quarter 2016 financial results news release will be issued Tuesday, October 25 after the close of trading on the New York Stock Exchange.
A conference call to review the financial results is planned on Wednesday, October 26 at 9:00 a.m. ET (8:00 a.m. CT). To take part in the call, please dial 866-900-7525 and provide conference code 92858145 about 10 minutes before the planned start time.